Related references
Note: Only part of the references are listed.A randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
Massimo Cristofanilli et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
Stephen R. D. Johnston et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D. W. Miles et al.
BRITISH JOURNAL OF CANCER (2013)
Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
Lee S. Schwartzberg et al.
CLINICAL CANCER RESEARCH (2013)
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2013)
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
William J. Gradishar et al.
EUROPEAN JOURNAL OF CANCER (2013)
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
David M. Hyams et al.
INVESTIGATIONAL NEW DRUGS (2013)
Diagnostic Value of Contrast-Enhanced Ultrasound Parametric Imaging in Breast Tumors
Zhang Yuan et al.
JOURNAL OF BREAST CANCER (2013)
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
18F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer
Jingyi Cheng et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron et al.
LANCET ONCOLOGY (2013)
Role of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging in the Management of Hepatocellular Carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan
Masatoshi Kudo et al.
ONCOLOGY (2013)
Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer
R. Joseph Bender et al.
PLOS ONE (2013)
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
Jose Baselga et al.
TRIALS (2013)
Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy
Thomas D. O'Sullivan et al.
BREAST CANCER RESEARCH (2013)
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A. M. Van der Veldt et al.
CANCER CELL (2012)
Baseline Tumor Oxygen Saturation Correlates with a Pathologic Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Shigeto Ueda et al.
CANCER RESEARCH (2012)
Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials
John R. Mackey et al.
CANCER TREATMENT REVIEWS (2012)
Sorafenib in locally advanced or metastatic breast cancer
William J. Gradishar
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
Katalin Boer et al.
INVESTIGATIONAL NEW DRUGS (2012)
Standardization of Dynamic Contrast-Enhanced Ultrasound for the Evaluation of Antiangiogenic Therapies The French Multicenter Support for Innovative and Expensive Techniques Study
Nathalie Lassau et al.
INVESTIGATIVE RADIOLOGY (2012)
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
Hope S. Rugo
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer
Robert S. Kerbel
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2012)
Evaluation of Breast Tumor Blood Flow with Dynamic First-Pass 18F-FDG PET/CT: Comparison with Angiogenesis Markers and Prognostic Factors
Alexandre Cochet et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
Jean-Yves Pierga et al.
LANCET ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
James P. B. O'Connor et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
Christoph Thomssen et al.
ONCOLOGY (2012)
Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging-Prospective Assessment
Ukihide Tateishi et al.
RADIOLOGY (2012)
POTENTIAL APPLICATION VALUE OF CONTRAST-ENHANCED ULTRASOUND IN NEOADJUVANT CHEMOTHERAPY OF BREAST CANCER
Xiaoli Cao et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2012)
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
Jose R. Rossari et al.
JOURNAL OF ONCOLOGY (2012)
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
I. E. Smith et al.
ANNALS OF ONCOLOGY (2011)
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study
Kenjiro Aogi et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
Nicholas J. Robert et al.
CLINICAL BREAST CANCER (2011)
A Double-blind, Randomized Phase IIb Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial
G. Mariani et al.
EUROPEAN JOURNAL OF CANCER (2011)
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
Xavier Pivot et al.
EUROPEAN JOURNAL OF CANCER (2011)
Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Adam M. Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A clinically relevant gene signature in triple negative and basal-like breast cancer
Achim Rody et al.
BREAST CANCER RESEARCH (2011)
Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
Mizuki Nishino et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2010)
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
H. Wildiers et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Antiangiogenic Therapies in Early-Stage Breast Cancer
Christina Derleth et al.
CLINICAL BREAST CANCER (2010)
Antiangiogenic strategies in breast cancer management
Monica Giovannini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
Late Release of Circulating Endothelial Cells and Endothelial Progenitor Cells after Chemotherapy Predicts Response and Survival in Cancer Patients
J. M. Roodhart et al.
NEOPLASIA (2010)
TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer
John Mackey et al.
CLINICAL BREAST CANCER (2009)
A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers
Joseph Baar et al.
CLINICAL CANCER RESEARCH (2009)
An overview of small-molecule inhibitors of VEGFR signaling
S. Percy Ivy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Harold J. Burstein et al.
CLINICAL CANCER RESEARCH (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inflammatory breast cancer: Dynamic contrast-enhanced MR in patients receiving bevacizumab - Initial experience
Arpi Thukral et al.
RADIOLOGY (2007)
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
Patrizia Mancuso et al.
BLOOD (2006)
Vascular endothelial growth factor expression in the basal subtype of breast carcinoma
A Ribeiro-Silva et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer:: antitumor activity and biological effects
M Colleoni et al.
ANNALS OF ONCOLOGY (2006)
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy
R Munoz et al.
BREAST (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Tumor angiogenesis: past, present and the near future
RS Kerbel
CARCINOGENESIS (2000)
Share Paper
